Patent details

Basic Information

Publication number:

EP3823631

PCT Application Number:

EP2019069323

Type:

European Patent Granted for LU

Legal Status:

In force

Application number:

EP197592942

PCT Publication Number:

WO2020016335

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

METHODS OF TREATING HFPEF EMPLOYING DAPAGLIFLOZIN AND COMPOSITIONS COMPRISING THE SAME

French Title of Invention:

MÉTHODES DE TRAITEMENT DE HFPEF AU MOYEN DE DAPAGLIFLOZINE ET COMPOSITIONS COMPRENANT CELLE-CI

German Title of Invention:

VERFAHREN ZUR BEHANDLUNG VON HFPEF MIT DAPAGLIFLOZIN UND ZUSAMMENSETZUNGEN DAMIT

SPC Number:

Dates

Filing date:

18/07/2019

Grant date:

20/05/2026

EP Publication Date:

26/05/2021

PCT Publication Date:

23/01/2020

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

20/05/2026

EP B1 Publication Date:

20/05/2026

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

Expiration date:

18/07/2039

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

13/05/2026

 

 

Name:

Astrazeneca AB

Address:

., 151 85 Södertälje, Sweden (SE)

Inventor

Name:

LANGKILDE, Anna, Maria

Address:

Sweden (SE)

Priority

Priority Number:

201862700463 P

Priority Date:

19/07/2018

Priority Country:

United States (US)

Classification

IPC classification:

A61K 31/70; A61P 9/00; A61P 9/04;

Publication

European Patent Bulletin

Issue number:

202621

Publication date:

20/05/2026

Description:

Grant (B1)

Annual Fees

Annual Fee Due Date:

31/07/2026

Annual Fee Number:

8

Annual Fee Amount:

99 Euro

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages